The number of people living with neurological disorders, such as Alzheimer’s disease, epilepsy, multiple sclerosis and Parkinson’s disease, has increased as the population has aged. At the same time, ...

Lecanemab reduces toxic amyloid-β protofibrils, slowing Alzheimer’s disease progression and supporting personalised treatment ...

The disease afflicts nearly seven million Americans, about one in every nine people over the age of 65, making it a leading ...

Nearly half a million people in England have received a dementia diagnosis in the past year, new NHS figures show.

LATE is a prevalent condition in late life and can contribute to memory loss and cognitive decline, according to report ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Access to the new Alzheimer's drugs is limited by strict eligibility criteria, long wait times, and a lack of infusion centers.

Additionally, the study highlighted that anti-inflammatory medications, such as ibuprofen, were correlated with a lower risk of dementia, aligning with the prevailing belief that inflammation plays a ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...

New guidelines will help doctors identify patients with a common memory-loss syndrome that is often misdiagnosed as Alzheimer's disease in older adults. The diagnostic criteria for limbic-predominant ...

As part of the regulatory action, memantine/donepezil extended-release capsules have been granted a 180-day exclusivity in patients with Alzheimer disease, with Everolimus receiving approval for ...

Xenon gas, currently used in medicine as an anesthetic and neuroprotective agent for treating brain injuries, showed potential in protecting the brain in studies.